Direxion Files Two Triple-Leveraged Pharmaceutical ETFs

direxion_logoPharmaceuticals – one of the hottest sectors of 2014 – has continued with its winning momentum this year as well on the back of several mergers and acquisitions. Moreover, impressive earnings in Q1 have helped to keep up the trend.

The bullish sentiment in the space is attracting issuers to come up with funds focusing on the space. Direxion, the second largest leader in the leverage and inverse ETF world, plans to launch a pair of ETFs targeting this growing sector by employing triple leverage.

Direxion Funds in Focus

The duo looks to give investors daily resetting exposure to Dynamic Pharmaceutical Intellidex Index with Direxion Daily Pharmaceutical Bull 2x Shares using 200% exposure and Direxion Daily Pharmaceutical Bear 2x Shares delivering a -200% return.

The index provides exposure to U.S. pharmaceutical companies principally engaged in research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The index might also include companies that facilitate the testing or regulatory approval of drugs.

The index uses a proprietary model that ranks the stocks for capital appreciation potential. The index includes 40% large cap and 60% small cap stocks selected from 2,000 largest companies listed on the NYSE MKT and NASDAQ. Sector-wise, the fund is expected to provide exposure to financial, technology, consumer discretionary, health care and producer durable industries.

The fund might use financial instruments such as swap agreements; futures contracts; equity caps, floors and collars; forward contracts; reverse repurchase agreements and ETFs to provide leveraged and unleveraged exposure to the Index.

How Do They Fit in a Portfolio?

Due to the daily resetting nature of these leveraged ETFs, the duo involves a high degree of risk when compared to traditional funds in the space and are hence not suitable for long-term bets. Rather, these should be utilized by high-risk tolerant traders seeking to play for the short term.

This is especially true given that investing through derivative instruments increases volatility. Further, the daily rebalancing — when combined with leverage — may make these products deviate significantly from the expected long-term performance figures.

Mergers and acquisitions have continued to play a major role in the Pharmaceuticals sector this year as well. Moreover, the health care sector was one of the top contributors to both S&P 500 earnings and revenue growth during Q1. Moreover, restructuring activities are also gaining momentum as large pharma companies are looking to cut costs and streamline their operations.

However, lofty valuations continue to remain a concern in this sector and could negatively affect the performance of the sector.

(…)Click here to continue reading the original ETFDailyNews.com article: Direxion Files Two Triple-Leveraged Pharmaceutical ETFs
You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (www.etfdailynews.com)